Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MARK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MARK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MARK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MARK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MARK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MARK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MARK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00451971 | Colorectum | SER | establishment or maintenance of epithelial cell apical/basal polarity | 16/2897 | 44/18723 | 5.64e-04 | 7.83e-03 | 16 |
GO:00350881 | Colorectum | SER | establishment or maintenance of apical/basal cell polarity | 17/2897 | 49/18723 | 7.17e-04 | 9.44e-03 | 17 |
GO:00612451 | Colorectum | SER | establishment or maintenance of bipolar cell polarity | 17/2897 | 49/18723 | 7.17e-04 | 9.44e-03 | 17 |
GO:00300101 | Colorectum | SER | establishment of cell polarity | 37/2897 | 143/18723 | 8.72e-04 | 1.06e-02 | 37 |
GO:00109751 | Colorectum | SER | regulation of neuron projection development | 92/2897 | 445/18723 | 1.85e-03 | 1.89e-02 | 92 |
GO:00313461 | Colorectum | SER | positive regulation of cell projection organization | 75/2897 | 353/18723 | 2.22e-03 | 2.14e-02 | 75 |
GO:00336741 | Colorectum | SER | positive regulation of kinase activity | 95/2897 | 467/18723 | 2.62e-03 | 2.41e-02 | 95 |
GO:00615641 | Colorectum | SER | axon development | 94/2897 | 467/18723 | 3.78e-03 | 3.13e-02 | 94 |
GO:00458601 | Colorectum | SER | positive regulation of protein kinase activity | 79/2897 | 386/18723 | 4.85e-03 | 3.79e-02 | 79 |
GO:00181051 | Colorectum | SER | peptidyl-serine phosphorylation | 66/2897 | 315/18723 | 5.47e-03 | 4.06e-02 | 66 |
GO:00074091 | Colorectum | SER | axonogenesis | 84/2897 | 418/18723 | 6.20e-03 | 4.49e-02 | 84 |
GO:00226042 | Colorectum | MSS | regulation of cell morphogenesis | 103/3467 | 309/18723 | 2.70e-10 | 2.56e-08 | 103 |
GO:00510982 | Colorectum | MSS | regulation of binding | 113/3467 | 363/18723 | 3.55e-09 | 2.41e-07 | 113 |
GO:00224112 | Colorectum | MSS | cellular component disassembly | 130/3467 | 443/18723 | 1.44e-08 | 8.46e-07 | 130 |
GO:00071632 | Colorectum | MSS | establishment or maintenance of cell polarity | 72/3467 | 218/18723 | 1.90e-07 | 8.30e-06 | 72 |
GO:00160552 | Colorectum | MSS | Wnt signaling pathway | 124/3467 | 444/18723 | 6.06e-07 | 2.26e-05 | 124 |
GO:01987382 | Colorectum | MSS | cell-cell signaling by wnt | 124/3467 | 446/18723 | 7.83e-07 | 2.77e-05 | 124 |
GO:00004222 | Colorectum | MSS | autophagy of mitochondrion | 33/3467 | 81/18723 | 2.70e-06 | 8.13e-05 | 33 |
GO:00617262 | Colorectum | MSS | mitochondrion disassembly | 33/3467 | 81/18723 | 2.70e-06 | 8.13e-05 | 33 |
GO:19030082 | Colorectum | MSS | organelle disassembly | 42/3467 | 114/18723 | 2.98e-06 | 8.91e-05 | 42 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MARK2 | SNV | Missense_Mutation | | c.2144N>A | p.Arg715His | p.R715H | Q7KZI7 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
MARK2 | SNV | Missense_Mutation | | c.2050G>C | p.Glu684Gln | p.E684Q | Q7KZI7 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MARK2 | SNV | Missense_Mutation | novel | c.1312G>C | p.Glu438Gln | p.E438Q | Q7KZI7 | protein_coding | tolerated(0.23) | benign(0.018) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MARK2 | SNV | Missense_Mutation | | c.1075C>A | p.Leu359Met | p.L359M | Q7KZI7 | protein_coding | deleterious(0.01) | possibly_damaging(0.654) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
MARK2 | SNV | Missense_Mutation | | c.316N>C | p.Val106Leu | p.V106L | Q7KZI7 | protein_coding | tolerated(0.79) | benign(0) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MARK2 | SNV | Missense_Mutation | rs368859674 | c.1307N>A | p.Arg436Gln | p.R436Q | Q7KZI7 | protein_coding | tolerated(0.79) | benign(0.007) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
MARK2 | SNV | Missense_Mutation | rs199684279 | c.905N>A | p.Arg302Gln | p.R302Q | Q7KZI7 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-XX-A899-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
MARK2 | insertion | Nonsense_Mutation | novel | c.908_909insCCCCAGAACTCTTCCAGGGCAAAAAATATGATGGACCC | p.Trp303CysfsTer11 | p.W303Cfs*11 | Q7KZI7 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MARK2 | insertion | Frame_Shift_Ins | novel | c.876_877insTCCTCTC | p.Gly293SerfsTer21 | p.G293Sfs*21 | Q7KZI7 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
MARK2 | insertion | Nonsense_Mutation | novel | c.879_880insCTCTGGTCTTAGCCCTGACCTCCTGCCTTTGCC | p.Gly293_Thr294insLeuTrpSerTerProTerProProAlaPheAla | p.G293_T294insLWS*P*PPAFA | Q7KZI7 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | TOZASERTIB | TOZASERTIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | LINIFANIB | LINIFANIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | DOVITINIB | DOVITINIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GSK-269962A | GSK-269962A | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | TYROSINE KINASE INHIBITORS | | 15811957 |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GNF-PF-2301 | CHEMBL578061 | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | KENPAULLONE | KENPAULLONE | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | CENISERTIB | CENISERTIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | ALSTERPAULLONE | ALSTERPAULLONE | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | AZD-1080 | AZD-1080 | |